John J Wright
Overview
Explore the profile of John J Wright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
5303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eisermann J, Liang Y, Wright J, Clifford E, Wilton-Ely J, Kuimova M, et al.
Chemistry
. 2024 Jul;
30(55):e202402035.
PMID: 39058376
Respiratory complex I (R-CI) is an essential enzyme in the mitochondrial electron transport chain but also a major source of reactive oxygen species (ROS), which are implicated in neurodegenerative diseases...
2.
Grba D, Wright J, Yin Z, Fisher W, Hirst J
Science
. 2024 Jun;
384(6701):1247-1253.
PMID: 38870289
Respiratory complex I is an efficient driver for oxidative phosphorylation in mammalian mitochondria, but its uncontrolled catalysis under challenging conditions leads to oxidative stress and cellular damage. Ischemic conditions switch...
3.
Gong J, Mita A, Wei Z, Cheng H, Mitchell E, Wright J, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300406.
PMID: 38603651
Purpose: Despite fibroblast growth factor receptor () inhibitors being approved in tumor types with select rearrangements or gene mutations, amplifications of represent the most common alteration across malignancies. Subprotocol K1...
4.
Gong J, Mita A, Wei Z, Cheng H, Mitchell E, Wright J, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300407.
PMID: 38603650
Purpose: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients...
5.
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, et al.
Clin Cancer Res
. 2024 Mar;
30(7):1273-1280.
PMID: 38433347
Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across...
6.
Eisermann J, Wright J, Wilton-Ely J, Hirst J, Roessler M
RSC Chem Biol
. 2023 Jun;
4(6):386-398.
PMID: 37292059
Complex I is an essential membrane protein in respiration, oxidising NADH and reducing ubiquinone to contribute to the proton-motive force that powers ATP synthesis. Liposomes provide an attractive platform to...
7.
Chung I, Grba D, Wright J, Hirst J
Curr Opin Struct Biol
. 2022 Sep;
77():102447.
PMID: 36087446
Respiratory complex I (NADH:ubiquinone oxidoreductase) is a multi-subunit, energy-transducing mitochondrial enzyme that is essential for oxidative phosphorylation and regulating NAD/NADH pools. Despite recent advances in structural knowledge and a long...
8.
Chung I, Wright J, Bridges H, Ivanov B, Biner O, Pereira C, et al.
Nat Commun
. 2022 May;
13(1):2758.
PMID: 35589726
Mitochondrial complex I is a central metabolic enzyme that uses the reducing potential of NADH to reduce ubiquinone-10 (Q) and drive four protons across the inner mitochondrial membrane, powering oxidative...
9.
Wright J, Biner O, Chung I, Burger N, Bridges H, Hirst J
J Am Chem Soc
. 2022 Apr;
144(15):6791-6801.
PMID: 35380814
Respiratory complex I is an essential metabolic enzyme that uses the energy from NADH oxidation and ubiquinone reduction to translocate protons across an energy transducing membrane and generate the proton...
10.
Damodaran S, Zhao F, Deming D, Mitchell E, Wright J, Gray R, et al.
J Clin Oncol
. 2022 Feb;
40(14):1552-1561.
PMID: 35133871
Purpose: Activating mutations in are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic...